Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group
Details
Publication Year 2026-09,Volume 27,Issue #9,Page e420-e433
Journal Title
Lancet Oncology
Publication Type
Review
Abstract
Tumour-infiltrating lymphocytes (TILs) are prognostic and predictive biomarkers in breast cancer. High pre-treatment TILs are associated with a favourable prognosis and improved response to systemic therapies. However, the role of TILs in mediating response to radiotherapy in breast cancer remains underexplored, with scarce clinical evidence to date. In this Review, we present an overview of current evidence and potential mechanisms, highlight opportunities for integrating TILs into radiation oncology trials and clinical practice, and call for standardised TIL reporting to accelerate biomarker-driven individualisation of radiotherapy in breast cancer.
Publisher
Elsevier
Keywords
Humans; *Lymphocytes, Tumor-Infiltrating/immunology/radiation effects; *Breast Neoplasms/radiotherapy/immunology/pathology; Female; *Biomarkers, Tumor/immunology; Prognosis
Department(s)
Laboratory Research; Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1016/s1470-2045(26)00255-x
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2026-11-12 06:04:09
Last Modified: 2026-11-12 06:04:17
An error has occurred. This application may no longer respond until reloaded. Reload 🗙